Lunit designates France as a key market within Europe and is actively expanding its business there
A high-level government delegation from France visited Lunit to discuss ways to expand medical artificial intelligence across Europe. (Photo courtesy of Lunit)
A high-level government delegation from France, including the head of national investment planning at the ministerial level, visited Lunit to discuss ways to expand medical artificial intelligence across Europe.
Lunit said on April 7 that officials from the General Secretariat for Investment (SGPI), which operates under the French Prime Minister’s Office, visited its headquarters in Gangnam, Seoul, on the previous day to discuss investment directions for medical AI technologies and potential cooperation in the public healthcare sectors in France and Europe.
The French delegation was led by Bruno Bonnell, secretary general of the SGPI at the ministerial level, and included Catherine Simon, specialist for robotics; Mathieu Brandibat, specialist for raw materials; Marion Dos Reis Silva, chief of staff and communications director; Matthieu Lefort, commercial counselor at the French Embassy in South Korea; and Oh Hyun-sook, commercial officer.
The SGPI is a key control tower directly under the French Prime Minister’s Office that designs, coordinates and evaluates the national strategic investment program France 2030, which is worth 54 billion euros, or about $62.28 billion or 94 trillion won. The France 2030 program supports research and development and industrialization in strategic industries such as energy, artificial intelligence and bio-health. Secretary general Bonnell, a former lawmaker and a prominent entrepreneur who led digital and robotics firms, was appointed by President Emmanuel Macron to lead the plan.
At the meeting, Lunit CEO Seo Beom-seok introduced the company’s medical AI technology portfolio, global business status and business developments in European markets, including France. The two sides then held in-depth discussions focused on interest levels and investment directions for medical AI technologies in France and Europe, as well as policy insights in the public healthcare sector.
Meanwhile, Lunit has designated France as a key market within Europe and is actively expanding its business there. Last year, it was selected as a supplier in a bid by UniHA, France’s largest public healthcare purchasing cooperative, for a breast cancer diagnostic AI solution, securing a foundation to supply solutions to more than 1,500 public hospitals. It has also established a supply channel to around 400 medical institutions through a partnership with Groupe VIDI, a French diagnostic imaging network.
Choi Mun-hee
댓글
0